AMD Pathology
ActiveSummary
AMD Pathology has been active since 2023 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €218,580 and a net result of €211,988. Equity is growing by about 110% per year across the filed financial years. The computed 12-month bankruptcy probability is 0.1% (very low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
30-08
NBB filing
Annual accounts filed
financial year 2025 · micro format · 30 days late
2025
31-12
Financial
Highest result from 2023 to 2025net €211,988 ▲82.2%
Operating result €275,509, net result €211,988, both a record.
31-12
Financial
Equity above €200,000equity €218,580 ▲109%
2 profitable years in a row build equity to €218,580.
28-08
NBB filing
Annual accounts filed
financial year 2024 · micro format · 28 days late
2024
31-12
Financial
Back to profitnet €116,324
Net result €116,324 after one loss-making year.
31-12
Financial
Liquidity more than 36 timescurrent ratio 7.21
Current ratio from 0.20 to 7.21; short-term debt falls from €15,781 to €14,868.
31-12
Financial
Equity above €100,000equity €104,592
Equity rises from -€11,732 to €104,592.
30-08
NBB filing
Annual accounts filed
financial year 2023 · micro format · 30 days late
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
0 of 2 deeds read
About the unread acts
We know of 2 Belgian Official Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.